Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

The data presented highlights cases in individuals under 18 years of age:

  • Newborns: 0–1 month
  • Infants: 2–12 months
  • Toddlers: 1–4 years
  • Children: 5–14 years
  • Teenagers: 15–18 years

Total cases

35

Confirmed cases

15

Total PLWH

1

Total deaths

0

Girls

51.4%

Newborns (0-1 mo)

0

Infant (2–12 mo)

2

Children (1-4 yrs)

12

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Distribution
Cases reported
Mirror plots by age group
Mirror plots by developmental stages
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 35 2.9% 1 / 35
Chronic heart disease 35 0.0% 0 / 35
Hypertension 35 0.0% 0 / 35
Chronic lung disease 35 0.0% 0 / 35
Chronic kidney disease 35 0.0% 0 / 35
Chronic liver disease 35 0.0% 0 / 35
Chronic neurologic condition 35 0.0% 0 / 35
Current alcohol use disorder 35 0.0% 0 / 35
Previous COVID-19 infection 35 0.0% 0 / 35
Diabetes 35 0.0% 0 / 35
Currently smokes tobacco 35 0.0% 0 / 35
Skin Conditions 35 0.0% 0 / 35
Tuberculosis (previous) 35 0.0% 0 / 35
Tuberculosis (active) 35 0.0% 0 / 35
Asplenia 35 0.0% 0 / 35
Cancer 35 0.0% 0 / 35
Immunosuppressive condition 35 0.0% 0 / 35
Current new STI (Sexually Transmitted Infection) diagnosis? 35 0.0% 0 / 35
AIDS - defining illness 1 0.0% 0 / 1

Source: WHO
Download as PNG Download as PDF
Complications
Variable Sample size Prevalence pct Frequency
Bacteraemia 35 14.3% 5 / 35
Cellulitis 35 11.4% 4 / 35
Anaemia 35 5.7% 2 / 35
Bacterial Pneumonia 35 5.7% 2 / 35
Ocular Complications 35 5.7% 2 / 35
Viral Pneumonia / Pneumonitis 35 2.9% 1 / 35
Abscess 35 2.9% 1 / 35
Sepsis 35 0.0% 0 / 35
Shock 35 0.0% 0 / 35
Seizure 35 0.0% 0 / 35
Encephalitis / Meningitis 35 0.0% 0 / 35
Bleeding Disorder 35 0.0% 0 / 35
Stroke / Cerebrovascular Accident 35 0.0% 0 / 35
Guillain-BarrΓ© Syndrome 35 0.0% 0 / 35
Cardiac Arrest 35 0.0% 0 / 35
Cardiac Arrhythmia 35 0.0% 0 / 35
Cardiomyopathy 35 0.0% 0 / 35
Myocarditis / Pericarditis 35 0.0% 0 / 35
Acute Respiratory Distress Syndrome (Ards) 35 0.0% 0 / 35
Acute Renal Injury / Acute Renal Failure 35 0.0% 0 / 35
Pancreatitis 35 0.0% 0 / 35
Liver Dysfunction 35 0.0% 0 / 35
Urinary Retention 35 0.0% 0 / 35
Necrotizing Infection 35 0.0% 0 / 35
Proctitis 35 0.0% 0 / 35
Rectal Urgency 35 0.0% 0 / 35
Rectal Pain 35 0.0% 0 / 35

Source: WHO
Download as PNG Download as PDF
Body map of lesions at admission
Variable Sample size Prevalence pct Frequency
Papule 35 74.3% 26/35
Macule 35 57.1% 20/35
Small pustule 35 45.7% 16/35
Crusting of a mature lesion 35 40.0% 14/35
Early vesicle 35 37.1% 13/35
Umbilicated pustule 35 25.7% 9/35
Ulcerated lesion 35 20.0% 7/35
Partially removed scab 35 17.1% 6/35

Source: WHO
Download as PNG Download as PDF
Variable Sample size Prevalence pct Frequency
Upper limb 35 88.6% 31/35
Head and neck 35 85.7% 30/35
Back 35 80.0% 28/35
Lower limb 35 80.0% 28/35
Chest and abdomen 35 77.1% 27/35
Mouth 35 20.0% 7/35
Genitals 35 20.0% 7/35

Source: WHO
Download as PNG Download as PDF
Lesions by developmental stage
Reported symptoms
Symptoms by developmental group
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Fever 35 91.4% 32 / 35
Pruritis/itching 35 62.9% 22 / 35
Headache 35 42.9% 15 / 35
Fatigue or malaise 35 40.0% 14 / 35
Muscle pain or aching 35 31.4% 11 / 35
Sore throat 35 28.6% 10 / 35
Pain in mouth 35 17.1% 6 / 35
Swallowing problem 35 17.1% 6 / 35
Joint pain or aching 35 17.1% 6 / 35
Painful swallow 6 100.0% 6 / 6
Ocular symptoms (pain, redness, visual loss) 35 11.4% 4 / 35
Red eye(s) 4 100.0% 4 / 4
Vomiting 35 8.6% 3 / 35
Difficult swallow 6 50.0% 3 / 6
Eye pain 4 75.0% 3 / 4
Diarrhoea 35 5.7% 2 / 35
Nausea 35 2.9% 1 / 35
Urinary symptoms 35 2.9% 1 / 35
Pain with urination 1 100.0% 1 / 1
Any rectal symptom 35 0.0% 0 / 35
Chest pain 35 0.0% 0 / 35
Proctitis 35 0.0% 0 / 35
Dizziness 35 0.0% 0 / 35
Psychologic disturbance 35 0.0% 0 / 35
Visual disturbance 4 0.0% 0 / 4
Other 4 0.0% 0 / 4
...with blood 3 0.0% 0 / 3
Decrease urine output 1 0.0% 0 / 1
Urethral discharge 1 0.0% 0 / 1

Source: WHO
Download as PNG Download as PDF
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Sore throat 35 2.9% 1 / 35
Fever 35 0.0% 0 / 35
Pruritis/itching 35 0.0% 0 / 35
Muscle pain or aching 35 0.0% 0 / 35
Headache 35 0.0% 0 / 35
Ocular symptoms (pain, redness, visual loss) 35 0.0% 0 / 35
Fatigue or malaise 35 0.0% 0 / 35
Pain in mouth 35 0.0% 0 / 35
Nausea 35 0.0% 0 / 35
Vomiting 35 0.0% 0 / 35
Diarrhoea 35 0.0% 0 / 35
Any rectal symptom 35 0.0% 0 / 35
Swallowing problem 35 0.0% 0 / 35
Chest pain 35 0.0% 0 / 35
Joint pain or aching 35 0.0% 0 / 35
Proctitis 35 0.0% 0 / 35
Dizziness 35 0.0% 0 / 35
Psychologic disturbance 35 0.0% 0 / 35
Urinary symptoms 35 0.0% 0 / 35

Source: WHO
Download as PNG Download as PDF
HIV demographics by age group
Variable

Infant (2 – 12 months)
N = 2

Toddler (1- 4 years)
N = 12

Child (5- 14 years)
N = 16

Teenager (15- 19 years)
N = 5

 p-value 1
HIV status, n (%)



>0.9
    Person with HIV 0 (0%) 0 (0%) 1 (6.3%) 0 (0%)
    Person without HIV 2 (100%) 11 (92%) 14 (88%) 5 (100%)
    Unknown 0 (0%) 1 (8.3%) 1 (6.3%) 0 (0%)
Sex at birth, n (%)



0.7
    Male 1 (50%) 4 (33%) 9 (56%) 3 (60%)
    Female 1 (50%) 8 (67%) 7 (44%) 2 (40%)
    Intersex 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Race, n (%)



0.2
    African/Black 2 (100%) 10 (83%) 16 (100%) 4 (80%)
    Arab 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Unknown 0 (0%) 2 (17%) 0 (0%) 1 (20%)
    Other 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Immunosuppressive condition, n (%)



>0.9
    Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    No 2 (100%) 12 (100%) 16 (100%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
1

Fisher’s exact test
Download as PNG Download as PDF
Vaccination data by age group
Variable

Infant (2 – 12 months)
N = 2

Toddler (1- 4 years)
N = 12

Child (5- 14 years)
N = 16

Teenager (15- 19 years)
N = 5

 p-value 1
HIV status, n (%)



>0.9
    Person with HIV 0 (0%) 0 (0%) 1 (6.3%) 0 (0%)
    Person without HIV 2 (100%) 11 (92%) 14 (88%) 5 (100%)
    Unknown 0 (0%) 1 (8.3%) 1 (6.3%) 0 (0%)
History of tetanus vaccination, n (%)



0.3
    Yes 0 (0%) 3 (25%) 3 (19%) 0 (0%)
    No 2 (100%) 6 (50%) 4 (25%) 2 (40%)
    Unknown 0 (0%) 3 (25%) 9 (56%) 3 (60%)
History of smallpox vaccination before 1980, n (%)



0.7
    Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    No 2 (100%) 11 (92%) 13 (81%) 5 (100%)
    Unknown 0 (0%) 1 (8.3%) 3 (19%) 0 (0%)
History of smallpox or monkeypox vaccination in past year, n (%)



0.7
    Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    No 2 (100%) 11 (92%) 13 (81%) 5 (100%)
    Unknown 0 (0%) 1 (8.3%) 3 (19%) 0 (0%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 2 12 16 5
1

Fisher’s exact test
Download as PNG Download as PDF
Treatment metrics by age group
Variable

Infant (2 – 12 months)
N = 2

Toddler (1- 4 years)
N = 12

Child (5- 14 years)
N = 16

Teenager (15- 19 years)
N = 5

 p-value 1
HIV status, n (%)



>0.9
    Person with HIV 0 (0%) 0 (0%) 1 (6.3%) 0 (0%)
    Person without HIV 2 (100%) 11 (92%) 14 (88%) 5 (100%)
    Unknown 0 (0%) 1 (8.3%) 1 (6.3%) 0 (0%)
ever hospitalized, n (%)



0.6
    Yes 2 (100%) 11 (92%) 12 (75%) 5 (100%)
    No 0 (0%) 1 (8.3%) 4 (25%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Length of hospitalization, Median (Q1, Q3) 5 (4, 5) 6 (5, 7) 7 (5, 12) 6 (5, 12) 0.4
    Missing/Unknown 0 1 4 0
Escalation of care, n (%)



>0.9
    Yes 0 (0%) 0 (0%) 1 (8.3%) 0 (0%)
    No 2 (100%) 11 (100%) 11 (92%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 0 1 4 0
supplemental oxygen, n (%)



>0.9
    Yes 0 (0%) 0 (0%) 1 (8.3%) 0 (0%)
    No 2 (100%) 11 (100%) 11 (92%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 0 1 4 0
receive nasogastric fluids, n (%)



>0.9
    Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    No 2 (100%) 12 (100%) 16 (100%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
receive IV fluids during course monkeypox infection, n (%)



>0.9
    Yes 0 (0%) 0 (0%) 1 (6.3%) 0 (0%)
    No 2 (100%) 12 (100%) 15 (94%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
receive analgesia for pain management, n (%)



0.4
    Yes 0 (0%) 3 (25%) 6 (38%) 0 (0%)
    No 2 (100%) 9 (75%) 10 (63%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
receive antibiotics during course monkeypox infection, n (%)



0.4
    Yes 1 (50%) 11 (92%) 14 (88%) 4 (80%)
    No 1 (50%) 1 (8.3%) 2 (13%) 1 (20%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
receive antifungals during course monkeypox infection, n (%)



>0.9
    Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    No 2 (100%) 12 (100%) 16 (100%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
experimental antiviral during course monkeypox infection, n (%)



>0.9
    Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    No 2 (100%) 12 (100%) 16 (100%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Download as PNG Download as PDF
Variable

Person with HIV
N = 1

Person without HIV
N = 32

Unknown
N = 2

 p-value 1
Age group, n (%)


0.8
    28-364 days 0 (0%) 2 (6.3%) 0 (0%)
    1-4 years 0 (0%) 11 (34%) 1 (50%)
    5-9 years 0 (0%) 8 (25%) 0 (0%)
    10-14 years 1 (100%) 6 (19%) 1 (50%)
    15-19 years 0 (0%) 5 (16%) 0 (0%)
Children group, n (%)


>0.9
    Infant (2 – 12 months) 0 (0%) 2 (6.3%) 0 (0%)
    Toddler (1- 4 years) 0 (0%) 11 (34%) 1 (50%)
    Child (5- 14 years) 1 (100%) 14 (44%) 1 (50%)
    Teenager (15- 19 years) 0 (0%) 5 (16%) 0 (0%)
Sex at birth, n (%)


0.5
    Male 1 (100%) 16 (50%) 0 (0%)
    Female 0 (0%) 16 (50%) 2 (100%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
Race, n (%)


>0.9
    African/Black 1 (100%) 29 (91%) 2 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 0 (0%) 3 (9.4%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 31 (97%) 2 (100%)
    Unknown 0 (0%) 1 (3.1%) 0 (0%)
Laboratory worker, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 30 (94%) 2 (100%)
    Unknown 0 (0%) 2 (6.3%) 0 (0%)
Sex worker, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 31 (97%) 2 (100%)
    Unknown 0 (0%) 1 (3.1%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (NA%) 0 (0%) 0 (0%)
    No 0 (NA%) 16 (100%) 2 (100%)
    Unknown 0 (NA%) 0 (0%) 0 (0%)
    Missing/Unknown 1 16 0
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 32 2
1

Fisher’s exact test
Download as PNG Download as PDF
Variable

Person with HIV
N = 1

Person without HIV
N = 32

Unknown
N = 2

 p-value 1
ever hospitalized, n (%)


>0.9
    Yes 1 (100%) 27 (84%) 2 (100%)
    No 0 (0%) 5 (16%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
Length of hospitalization, Median (Q1, Q3) 21 (21, 21) 6 (5, 9) 12 (6, 17) 0.11
    Missing/Unknown 0 5 0
Escalation of care, n (%)


0.033
    Yes 1 (100%) 0 (0%) 0 (0%)
    No 0 (0%) 27 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 0 5 0
supplemental oxygen, n (%)


0.033
    Yes 1 (100%) 0 (0%) 0 (0%)
    No 0 (0%) 27 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 0 5 0
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 32 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
receive IV fluids during course monkeypox infection, n (%)


0.029
    Yes 1 (100%) 0 (0%) 0 (0%)
    No 0 (0%) 32 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
receive analgesia for pain management, n (%)


0.2
    Yes 1 (100%) 7 (22%) 1 (50%)
    No 0 (0%) 25 (78%) 1 (50%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
receive antibiotics during course monkeypox infection, n (%)


>0.9
    Yes 1 (100%) 27 (84%) 2 (100%)
    No 0 (0%) 5 (16%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
receive antifungals during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 32 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 32 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Download as PNG Download as PDF
Variable

Person with HIV
N = 1

Person without HIV
N = 32

Unknown
N = 2

 p-value 1
History of tetanus vaccination, n (%)


0.5
    Yes 0 (0%) 5 (16%) 1 (50%)
    No 0 (0%) 13 (41%) 1 (50%)
    Unknown 1 (100%) 14 (44%) 0 (0%)
History of smallpox vaccination before 1980, n (%)


0.3
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 29 (91%) 1 (50%)
    Unknown 0 (0%) 3 (9.4%) 1 (50%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.3
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 29 (91%) 1 (50%)
    Unknown 0 (0%) 3 (9.4%) 1 (50%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 32 2
1

Fisher’s exact test
Download as PNG Download as PDF
Variable

Person with HIV
N = 1

Person without HIV
N = 32

Unknown
N = 2

 p-value 1
New diagnosis of HIV, n (%)


>0.9
    Yes 0 (0%) 1 (3.1%) 0 (0%)
    No 1 (100%) 31 (97%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 32 2
Immunosuppressive condition, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (100%) 32 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 0 32 2
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 0 (0%) 0 (NA%) 0 (NA%)
    Unknown 1 (100%) 0 (NA%) 0 (NA%)
    Missing/Unknown 0 32 2
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 1 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 0 32 2
1

Fisher’s exact test
Download as PNG Download as PDF
Skin lesions by HIV status
Complications by HIV status
Variable

Confirmed case
N = 15

Not confirmed
N = 19

 p-value 1
HIV status, n (%)

0.2
    Person with HIV 0 (0%) 1 (5.3%)
    Person without HIV 13 (87%) 18 (95%)
    Unknown 2 (13%) 0 (0%)
Age group, n (%)

0.8
    28-364 days 1 (6.7%) 1 (5.3%)
    1-4 years 6 (40%) 5 (26%)
    5-9 years 2 (13%) 6 (32%)
    10-14 years 4 (27%) 4 (21%)
    15-19 years 2 (13%) 3 (16%)
Sex at birth, n (%)

>0.9
    Male 7 (47%) 10 (53%)
    Female 8 (53%) 9 (47%)
    Intersex 0 (0%) 0 (0%)
    Unknown 0 (0%) 0 (0%)
Race, n (%)

>0.9
    African/Black 14 (93%) 17 (89%)
    Arab 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%)
    Unknown 1 (6.7%) 2 (11%)
    Other 0 (0%) 0 (0%)
health care worker, n (%)

0.4
    Yes 0 (0%) 0 (0%)
    No 14 (93%) 19 (100%)
    Unknown 1 (6.7%) 0 (0%)
Laboratory worker, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 14 (93%) 18 (95%)
    Unknown 1 (6.7%) 1 (5.3%)
Sex worker, n (%)

0.4
    Yes 0 (0%) 0 (0%)
    No 14 (93%) 19 (100%)
    Unknown 1 (6.7%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 8 (100%) 9 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 7 10
Breastfeeding, n (%)


    Yes 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%)
    Missing/Unknown 15 19
1

Fisher’s exact test
Download as PNG Download as PDF
Variable

Confirmed case
N = 15

Not confirmed
N = 19

 p-value 1
HIV status, n (%)

0.2
    Person with HIV 0 (0%) 1 (5.3%)
    Person without HIV 13 (87%) 18 (95%)
    Unknown 2 (13%) 0 (0%)
ever hospitalized, n (%)

0.4
    Yes 14 (93%) 15 (79%)
    No 1 (6.7%) 4 (21%)
    Unknown 0 (0%) 0 (0%)
Length of hospitalization, Median (Q1, Q3) 6 (5, 9) 6 (4, 10) 0.3
    Missing/Unknown 1 4
Escalation of care, n (%)

>0.9
    Yes 0 (0%) 1 (6.7%)
    No 14 (100%) 14 (93%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 4
supplemental oxygen, n (%)

>0.9
    Yes 0 (0%) 1 (6.7%)
    No 14 (100%) 14 (93%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 4
receive nasogastric fluids, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 15 (100%) 19 (100%)
    Unknown 0 (0%) 0 (0%)
receive IV fluids during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 1 (5.3%)
    No 15 (100%) 18 (95%)
    Unknown 0 (0%) 0 (0%)
receive analgesia for pain management, n (%)

>0.9
    Yes 4 (27%) 5 (26%)
    No 11 (73%) 14 (74%)
    Unknown 0 (0%) 0 (0%)
receive antibiotics during course monkeypox infection, n (%)

>0.9
    Yes 13 (87%) 17 (89%)
    No 2 (13%) 2 (11%)
    Unknown 0 (0%) 0 (0%)
receive antifungals during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 15 (100%) 19 (100%)
    Unknown 0 (0%) 0 (0%)
experimental antiviral during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 15 (100%) 19 (100%)
    Unknown 0 (0%) 0 (0%)
1

Fisher’s exact test; Wilcoxon rank sum test
Download as PNG Download as PDF
Variable

Confirmed case
N = 15

Not confirmed
N = 19

 p-value 1
HIV status, n (%)

0.2
    Person with HIV 0 (0%) 1 (5.3%)
    Person without HIV 13 (87%) 18 (95%)
    Unknown 2 (13%) 0 (0%)
History of tetanus vaccination, n (%)

0.069
    Yes 3 (20%) 3 (16%)
    No 9 (60%) 5 (26%)
    Unknown 3 (20%) 11 (58%)
History of smallpox vaccination before 1980, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 13 (87%) 17 (89%)
    Unknown 2 (13%) 2 (11%)
History of smallpox or monkeypox vaccination in past year, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 13 (87%) 17 (89%)
    Unknown 2 (13%) 2 (11%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 15 19
1

Fisher’s exact test
Download as PNG Download as PDF
Variable

Confirmed case
N = 15

Not confirmed
N = 19

 p-value 1
HIV status, n (%)

0.2
    Person with HIV 0 (0%) 1 (5.3%)
    Person without HIV 13 (87%) 18 (95%)
    Unknown 2 (13%) 0 (0%)
New diagnosis of HIV, n (%)

0.4
    Yes 1 (6.7%) 0 (0%)
    No 14 (93%) 19 (100%)
    Unknown 0 (0%) 0 (0%)
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)


    Yes 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%)
    Missing/Unknown 15 19
Immunosuppressive condition, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 15 (100%) 19 (100%)
    Unknown 0 (0%) 0 (0%)
Most recent CD4, Median (Q1, Q3) NA (NA, NA) 98 (98, 98)
    Missing/Unknown 15 18
Viral load, n (%)


    Detectable 0 (NA%) 0 (0%)
    Undetectable 0 (NA%) 0 (0%)
    Unknown 0 (NA%) 1 (100%)
    Missing/Unknown 15 18
AIDS - defining illness, n (%)


    Yes 0 (NA%) 0 (0%)
    No 0 (NA%) 1 (100%)
    Unknown 0 (NA%) 0 (0%)
    Missing/Unknown 15 18
1

Fisher’s exact test
Download as PNG Download as PDF
Skin lesions by mpox status
Complications
Exposure distribution
Variable Sample size Prevalence pct Frequency
Any known link to probable or confirmed case of monkeypox within ≀ 21 days prior to symptom onset? 35 20.0% 7/35
Sexually active within ≀ 21 days prior to symptom onset? 35 2.9% 1/35
International travel within ≀ 21 days prior to symptom onset? 35 2.9% 1/35
Number of heterosexual partners in the last three months 1 100.0% 1/1
Contact with possible animal source within ≀ 21 days prior to symptom onset? 35 0.0% 0/35
Did the patient receive experimental antiviral during course monkeypox infection? 35 0.0% 0/35

Source: WHO
Download as PNG Download as PDF
Variable N = 35
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 35 (100%)
    Unknown 0 (0%)
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 35
Monkeypox PCR, n (%)
    Yes 34 (97%)
    No 1 (2.9%)
    Unknown 0 (0%)
Monkeypox Result, n (%)
    Positive 15 (44%)
    Negative 18 (53%)
    Indeterminate 0 (0%)
    Unknown 1 (2.9%)
    Missing/Unknown 1
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 35 (100%)
    Unknown 0 (0%)
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 35
Download as PNG Download as PDF
Variable N = 35
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 35 (100%)
    Unknown 0 (0%)
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 35
Download as PNG Download as PDF
Variable N = 35
Malaria result, n (%)
    Positive 0 (0%)
    Negative 3 (100%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 32
Syphilis result, n (%)
    Positive 0 (0%)
    Negative 1 (100%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 34
Download as PNG Download as PDF
Variable

Baseline visit
N = 35
Hemoglobin, Median (Q1, Q3) 12.60 (11.10, 14.60)
WCC total, Median (Q1, Q3) 6.7 (6.4, 10.4)
Platelets, Median (Q1, Q3) 255 (159, 332)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Download as PNG Download as PDF
Variable

During infection management
N = 35
Hemoglobin, Median (Q1, Q3) 12.70 (11.10, 14.00)
WCC total, Median (Q1, Q3) 8.8 (6.7, 10.4)
Platelets, Median (Q1, Q3) 282 (194, 386)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) 22 (22, 22)
AST, Median (Q1, Q3) 34 (34, 34)
Na+, Median (Q1, Q3) 134 (134, 134)
K+, Median (Q1, Q3) 4.1600 (4.1600, 4.1600)
Urea/BUN, Median (Q1, Q3) 6.3564 (6.3564, 6.3564)
Creatinine, Median (Q1, Q3) 32.7154 (32.7154, 32.7154)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Download as PNG Download as PDF
Variables Lab measures distribution
N Mean Median Min Max Distribution
Baseline visit
Hemoglobin 9.00 12.07 12.60 6.30 15.30
Platelets 9.00 296.44 255.00 132.00 731.00
WCC total 9.00 9.39 6.70 3.00 29.00
Download as PNG Download as PDF
Outcomes